The COVIDome online portal can rapidly accelerate coronavirus research worldwide

To further accelerate COVID-19 research on a global scale, investigators from the University of Colorado Anschutz Medical Campus have created a multidimensional dataset, known as the COVIDome dataset, derived from hospitalized COVID-19 patients versus negative controls. The team has now launched a public online portal called the COVIDome Explorer to share that data in real time.

Today, a new paper published in the journal Cell Reports detailing how the datasets were generated while explaining how to use the COVIDome Explorer for rapid hypotheses testing, hypothesis generation and real-time discoveries by experts and non-experts.

"Our mission for the COVIDome Explorer is to enable the development of better prevention, diagnostic and therapeutic tools for the clinical management of COVID-19," said Joaquin Espinosa, PhD, professor at the University of Colorado School of Medicine and executive director at the Linda Crnic Institute for Down Syndrome on the CU Anschutz Medical Campus. "Although great progress has been made in all these areas, the speed of research for COVID-19 has been hampered by the lack of widely accessible, public datasets that can be analyzed and reanalyzed in real time by anyone."

He adds, "We expect that this online portal will rapidly accelerate COVID-19 data sharing, hypothesis testing and discoveries worldwide."

To create the COVIDome Explorer, experts in different areas of biomedical research across the CU Anschutz Medical Campus created multidimensional datasets in their labs. Those were collected and combined to be shared through the online portal. The datasets include demographics and clinical data, along with matched analysis of the whole blood transcriptome, analysis of the plasma and red blood cell metabolomes, deep immune phenotyping by mass cytometry and seroconversion assays.

The COVIDome datasets and corresponding Explorer were modeled after similar ongoing efforts in the Linda Crnic Institute for Down Syndrome, where members of the COVIDome team previously developed the Human Trisome Project and its TrisomExplorer data portal. Leveraging the leading-edge tools and technologies of the TrisomExplorer, the team was able to create the COVIDome Explorer in a matter of weeks and make it available to the public to help advance COVID-19 research.

"The global health crisis imposed by the COVID-19 pandemic further emphasizes the need for rapid collaboration, open access to manuscripts under review and data sharing," said Thomas Flaig, MD, vice chancellor of research at the CU Anschutz Medical Campus. "Now more than ever, with the rise of the COVID-19 Delta variant and breakthrough infection rates rising, it’s critical to have easy and timely access to COVID data to combat the pandemic and advance the best scientific data available."

The paper, which users are encouraged to read, details how to use the online dashboards and links to data files that guide users, such as catalogs of proteins, metabolites, cytokines and immune cells present in each dataset.

For example, to facilitate quick and broad access to the COVIDome dataset, each dataset (after data curation and quality control) is linked at the sample level with a unique identifier, enabling cross-referencing among platforms. Additionally, the COVIDome Explorer hosts six dashboards: Cohort, Transcriptome, Proteome, Cytokines, Metabolome, and Immune Maps. And each dashboard runs within its own isolated and protected environment.

The COVIDome Project is a partnership between the CU School of Medicine and the Office of the Vice Chancellor for Research, co-led by Joaquin Espinosa, PhD, and Thomas Flaig, MD.

Sullivan KD, Galbraith MD, Kinning KT, Bartsch KW, Levinsky NC, Araya P, Smith KP, Granrath RE, Shaw JR, Baxter RM, Jordan KR, Russell SA, Dzieciatkowska ME, Reisz JA, Gamboni F, Cendali FI, Ghosh T, Monte AA, Bennett TD, Miller MG, Hsieh EW, D'Alessandro A, Hansen KC, Espinosa JM.
The COVIDome Explorer researcher portal. Cell Rep. 2021 Jul 28:109527. doi: 10.1016/j.celrep.2021.109527

Most Popular Now

Novartis provides more than USD 25 million in medi…

Novartis announced that it condemns the war in Ukraine: "The continued acts of unprovoked violence are harming innocent people, and this defies our mission to improve hum...

Findings open way for personalised MS treatment

Currently available therapies to treat multiple sclerosis (MS) lack precision and can lead to serious side effects. Researchers at Karolinska Institutet in Sweden have no...

Pfizer and Biohaven's VYDURA® (rimegepant) granted…

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorizatio...

Pfizer shares top-line results from Phase 2/3 EPIC…

Pfizer Inc. (NYSE: PFE) shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating...

A smarter way to develop new drugs

Pharmaceutical companies are using artificial intelligence to streamline the process of discovering new medicines. Machine-learning models can propose new molecules that ...

Cognitive impairment from severe COVID-19 equivale…

Cognitive impairment as a result of severe COVID-19 is similar to that sustained between 50 and 70 years of age and is the equivalent to losing 10 IQ points, say a team o...

A new toolkit to engineer safe and efficient thera…

Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer. Compared to traditional drugs, engineered immune cell...

SK bioscience and GSK's adjuvanted COVID-19 vaccin…

SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s...

Foundation S: Sanofi's new philanthropic spearhead

Sanofi today launches Foundation S - The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partners...

Asthma drug can block crucial SARS-CoV-2 protein

A drug used to treat asthma and allergies can bind to and block a crucial protein produced by the virus SARS-CoV-2, and reduce viral replication in human immune cells, ac...

Investigational COVID mucosal vaccine protects aga…

In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spr...

Using AI to analyze large amounts of biological da…

Researchers at the University of Missouri are applying a form of artificial intelligence (AI) - previously used to analyze how National Basketball Association (NBA) playe...